BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Cardiovascular Systems (CSII) in Focus: Stock Moves 8.4% Higher
by Zacks Equity Research
Cardiovascular Systems, Inc. (CSII) was a big mover last session, as the company saw its shares rise over 8% on the day.
Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.
Health Care Battle Rages On: 2 MedTech Stocks to Buy
by Zacks Equity Research
Let's focus on two MedTech Stocks which are fundamentally strong amidst the volatile market condition.
Capital Senior Living (CSU) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
Capital Senior Living Corporation (CSU) was a big mover last session, as the company saw its shares rise almost 6% on the day.
Omeros (OMER) Worth a Look: Stock Adds 11.8% in Session
by Zacks Equity Research
Omeros Corporation (OMER) shares rose almost 12% in the last trading session.
What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%
by Zacks Equity Research
Imprimis Pharmaceuticals, Inc. (IMMY) shares rose over 13% in the last trading session.
Five Stocks Rocketing Higher on Huge Momentum
by David Bartosiak
The bears were sent running, screaming towards their caves today as the market started strong and didn???t look back at all
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1
by Zacks Equity Research
TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.
STERIS (STE) Grapples with Headwinds: Should You Dump?
by Zacks Equity Research
On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.
Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.
Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.
Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip
by Zacks Equity Research
On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.
Becton (BDX) Announces $4.5B Follow-On Share Offerings
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.
STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.
New Strong Buy Stocks for May 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Medical Product Stocks' Earnings Due on May 4: ABMD & More
by Zacks Equity Research
Here we discuss four major Medical Product bigwigs, which are scheduled to release their earnings results on May 4.
MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their Oct-Dec 2016 numbers on Feb 23.
New Strong Sell Stocks for February 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: